Abstract
Cognitive deficits are a core feature of major depressive disorder (MDD). However, there are no previous studies that directly compare cognitive performance between first-episode drug-naive depressive patients (FDDP) and medicated depressive patients (MDP). Therefore, the aim of this study was to investigate whether there were the differences in cognitive functions between FDDP and MDP. Sixty-two FDDP, 111 MDP and 90 healthy controls were enrolled in a Chinese population. Cognitive functions were assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). There were the differences in the RBANS total score (F = 26.55, p < 0.001), subscales of immediate memory (F = 3.95, p = 0.02), language (F = 54.11, p < 0.001) and delayed memory (F = 11.19, p = 0.001) among the three groups after controlling for gender, education, smoking and body mass index (BMI). These differences in the RBANS total score, subscales of language and delayed memory passed the Bonferroni corrections (all, p < 0.05). Compared to healthy controls, FDDP and MDP had poorer cognitive performance including the RBANS total score, and subscales of language and delayed memory (all, p < 0.05) after controlling for the variables. FDDP experienced greater language deficits than MDP (p < 0.05) after controlling for the variables. Education was correlated with the language score in FDDP (r = 0.61, p < 0.001). Multivariate regression analysis indicated that education was an independent contributor to the language score in FDDP (ß = 3.11, t = 5.48, p < 0.001). Our findings indicated that FDDP had poorer language performance than MDP. Moreover, education could influence the language performance in FDDP.
Similar content being viewed by others
References
Afridi MI, Hina M, Qureshi IS, Hussain M. Cognitive disturbance comparison among drug-naïve depressed cases and healthy controls. J Coll Physicians Surg Pak. 2011;21(6):351–5.
Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44(10):2029–40.
Den Hartog HM, Derix MMA, Van Bemmel AL, Kremer B, Jolles J. Cognitive functioning in young and middle-aged unmediated out-patients with major depression: testing the effort and cognitive speed hypothesis. Psychol Med. 2003;33(8):1443–51.
Porter RJ, Bourke C, Gallagher P. Neuropsychological impairment in major depression: its nature, origin and clinical significance. Aust N Z J Psychiatry. 2007;41(2):115–28.
McDermott LM, Ebmeier KP. A meta-analysis of depression severity and cognitive function. J Affect Disord. 2009;119(1–3):1–8.
Lee RS, Hermens DF, Porter MA, Redoblado-Hodge MA. A meta-analysis of cognitive deficits in first-episode major depressive disorder. J Affect Disord. 2012;140(2):113–24.
Li M, Lu S, Wang G, Feng L, Fu B, Zhong N. Emotion, working memory, and cognitive control in patients with first-onset and previously untreated minor depressive disorders. J Int Med Res. 2016;44(3):529–41.
Li M, Zhong N, Lu SF, Wang G, Feng L, Hu B. Cognitive behavioral performance of untreated depressive patients with mild depressive symptoms. PLoS One. 2016;11:e0146356.
Millan MJ, Agid Y, Brüne M, Bullmore ET, Carter CS, Clayton NS, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 2012;11(2):141–68.
Baune B, Miller R, McAfoose J, Johnson M, Quirk F, Mitchell D. The role of cognitive impairment in general functioning in major depression. Psychiatry Res. 2010;176(2–3):183–9.
Shao TN, Yin GZ, Yin XL, Wu JQ, Du XD, Zhu HL, et al. Elevated triglyceride levels are associated with cognitive impairments among patients with major depressive disorder. Compr Psychiatry. 2017;75:103–9.
Hui L, Han M, Du XD, Zhang BH, He SC, Shao TN, et al. Serum Apo B levels in depressive patients: associated with cognitive deficits. Sci Rep. 2017;7:39992.
Basso MR, Bornstein RA. Relative memory deficits in recurrent verses first-episode major depression on a word-list learning task. Neuropsychology. 1999;13(4):557–63.
Stordal KL, Lundervold AJ, Egeland J, Mykletun A, AsbjØrnsen A, LandrØ NI, et al. Impairment across executive functions in recurrent major depression. Nord J Psychiatry. 2014;58(1):41–7.
Airaksinen E, Larsson M, Lundberg I, Forsell Y. Cognitive function in depression and anxiety depression. Psychol Med. 2004;34(1):83–91.
Kedzior KK, Rajput V, Price G, Lee J, Martin-lverson M. Cognitive correlates of repetitive transcranial magnetic stimulation (rTMS) in treatment-resistant depression-a pilot study. BMC Psychiatry. 2012;12:163.
Paradiso S, Duff K, Vaidya JG, Hoth A, Mold JW. Cognitive and daily functioning in older adults with vegetative symptoms of depression. Int J Geriatr Psychiatry. 2010;25(6):569–77.
Zhang BH, Tan YL, Zhang WF, Wang ZR, Yang GG, Shi C, et al. Repeatable battery for the assessment of neuropsychological status (RBANS) as a screening test in Chinese reliability and validity. Chin Ment Health J. 2008;12:865–9.
Hui L, Han M, Huang XF, Ye MJ, Zhang X, He JC, et al. Association between DBH 5′-insertion/deletion polymorphism and cognition in patients with chronic schizophrenia. J Clin Psychiatry. 2016;77(3):379–85.
Wang Y, Liu H, Zhang BS, Soares JC, Zhang XY. Low BDNF is associated with cognitive impairments in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2016;29:66–71.
Zhang XY, Tan YL, Chen DC, Tan SP, Yang FD, Zunta-Soares GB, et al. Effects of cigarette smoking and alcohol use on neurocognition and BDNF levels in a Chinese population. Psychopharmacology. 2016;233(3):435–45.
Zhen YF, Zhang J, Liu XY, Fang H, Tian LB, Zhou DH, et al. Low BDNF is associated with cognitive deficits in patients with type 2 diabetes. Psychopharmacology. 2013;227(1):93–100.
Randolph C, Tierney MC, Mohr E, Chase TN. The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol. 1998;20(3):310–9.
Austin MP, Ross M, Murray C, O’Carroll RE, Ebmeier KP, Goodwin GM. Cognitive function in major depression. J Affect Disord. 1992;25(1):21–9.
Ravnkilde B, Videbech P, Clemmensen K, Egander A, Rasmussen NA, Rosenberg R. Cognitive deficits in major depression. Scand J Psychol. 2002;43(3):239–51.
Hickie I, Naismith S, Ward PB, Turner K, Scott E, Mitchell P, et al. Reduced hippocampal volumes and memory loss in patients with early- and late-onset depression. Br J Psychiatry. 2005;186:197–202.
Frodl T, Schaub A, Banac S, Charypar M, Jäger M, Kümmler P, et al. Reduced hippocampal volume correlates with executive dysfunctioning in major depression. J Psychiatry Neurosci. 2006;31(5):316–23.
Gray JA, McNaughton N. Comparison between the behavioural effects of septal and hippocampal leisons: a review. Neurosci Biobehav Rev. 1983;7(2):119–88.
Xie Q, Liu Y, Li CY, Song XZ, Wang J, Han LX, et al. The modulation of venlafaxine on cortical activation of language area in healthy subjects with fMRI study. Psychopharmacology. 2012;223(4):417–25.
Péran P, Démonet JF, Cardebat D. Paroxetine-induced modulation of cortical activity supporting language representations of action. Psychopharmacology. 2008;195(4):487–96.
Walker-Batson D, Curtis S, Natarajan R, Ford J, Dronkers N, Salmeron E, et al. A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke. 2001;32(9):2093–8.
Feeney DM, Sutton RL. Pharmacotherapy for recovery of function after brain injury. Cirt Rev Neurobiol. 1987;3(2):135–97.
Berends HI, Nijlant JM, Movig KL, Van Putten MJ, Jannink MJ, Ijzerman MJ. The clinical use of drugs influencing neurotransmitters in the brain to promote motor recovery after stroke; a Cochrane systematic review. Eur J Phys Rehabil Med. 2009;45(4):621–30.
Duman RS, Nakagawa S, Malberg J. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology. 2001;25(6):836–44.
Mattson MP, Maudsley S, Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 2004;27(10):589–94.
Avila R, Moscoso MA, Ribeiz S, Arrais J, Jaluul O, Bottino CM. Influence of education and depressive symptoms on cognitive function in the elderly. Int Psychogeriatr. 2009;21(3):560–7.
McLaren ME, Szymkowicz SM, Kirton JW, Dotson VM. Impact of education on memory deficits in subclinical depression. Arch Clin Neuropsychol. 2015;30(5):387–93.
Wight RG, Aneshensel CS, Seeman TE. Educational attainment, continued learning experience, and cognitive function among older men. J Aging Health. 2002;14(2):211–36.
Cohen OS, Vakil E, Tanne D, Nitsan Z, Schwartz R, Hassin-Baer S. Educational level as a modulator of cognitive performance and neuropsychiatric features in Parkinson disease. Cogn Behav Neurol. 2007;20(1):68–72.
Stern Y. Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol. 2012;11(11):1006–12.
Arbuckle TY, Maag U, Pushkar D, Chaikelson JS. Individual differences in trajectory of intellectual development over 45 years of adulthood. Psychol Aging. 1998;13(4):663–75.
Evans DA, Beckett LA, Albert MS, Hebert LE, Scherr PA, Funkenstein HH, et al. Level of education and change in cognitive function in a community population of older persons. Ann Epidemiol. 1993;3(1):71–7.
Siedlecki KL, Stern Y, Reuben A, Sacco RL, Elkind MS, Wright CB. Construct validity of cognitive reserve in a multiethnic cohort: the northern Manhattan study. J Int Neuropsychol Soc. 2009;15(4):558–69.
Mitchell MB, Shaughnessy LW, Shirk SD, Yang FM, Atri A. Neuropsychological test performance and cognitive reserve in healthy aging and the Alzheimer’s disease spectrum: a theoretically driven factor analysis. J Int Neuropsychol Soc. 2012;18(6):1071–80.
O’Shea DM, Fieo RA, Hamilton JL, Zahodne LB, Manly JJ, Stern Y. Examining the association between late-life depressive symptoms, cognitive function, and brain volumes in the context of cognitive reserve. Int J Geriatr Psychiatry. 2015;30(6):614–22.
Acknowledgements
This study was funded by the grants from National Natural Science Foundation of China (81771439 and 81501160), Young Medical Talent of Jiangsu Province (QNRC2016228), Suzhou Key Medical Center for Psychiatric Diseases (Szzx201509), Suzhou Key Diagnosis and Treatment Program (LCZX201515), Suzhou Key Laboratory for Biological Psychiatry (SZS201722), Suzhou Municipal Sci-Tech Bureau Program (SS201706, and SYSD2017133), Wenzhou Municipal Sci-Tech Bureau Program (Y20170077), Health City “531” action plan of Suzhou Municipal, and Zhejiang Province Rising Star in Medicine. These sources had no further role in the design of this study, data collection and analysis, writing of the report, and decision to submit the paper for publication.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
No conflict of interest was disclosed for each author.
Human and Animal Rights
All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed Consent
Informed consent was obtained from all individual participants included in this study.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Qiu Fang Jia, Peng Chen, and Hong Liang Zhu regarded as joint first authors.
Rights and permissions
About this article
Cite this article
Jia, Q.F., Chen, P., Zhu, H.L. et al. Cognitive Impairments in First-Episode Drug-Naïve Versus Medicated Depressive Patients: RBANS in a Chinese Population. Psychiatr Q 90, 471–480 (2019). https://doi.org/10.1007/s11126-019-09641-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11126-019-09641-4